- Janssen/Parasol (MDG2001): A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD). Sponsor: Janssen Research & Development, LLC
- Pagoda (GR40550): A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA. Sponsor: F. Hoffmann-La Roche Ltd
- i-SIGHT (ILS-AMD-201): MICROCURRENT STIMULATION THERAPY FOR NONEXUDATIVE AGE- RELATED MACULAR DEGENERATION (I-SIGHT): A MULTICENTER, RANDOMIZED, SHAM-CONTROLLED, FEASIBILITY DEVICE TRIAL. Sponsor: i-Lumen Scientific, Inc.
- Portal (GR40549): A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Sponsor: F. Hoffmann-La Roche Ltd
- Ascent (RGX-314-3101): A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. Sponsor: AbbVie Inc.
- Opthea (OPT-302-1004): A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration. Sponsor: Opthea
- Aspire (UBX1325-04): A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema. Sponsor: UNITY Biotechnology, Inc.
- Verona (EYP-1901-202): A Phase 2, Multicenter, Prospective, Randomized, Single-Masked, Controlled Study of EYP-1901 (Vorolanib) Insert, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Diabetic Macular Edema (DME). Sponsor: EyePoint Pharmaceuticals, Inc.
- Perfuse (PER001-202): A PHASE 2A STUDY TO EVALUATE SAFETY AND TOLERABILITY AFTER SINGLE ADMINISTRATION OF PER-001 INTRAVITREAL IMPLANT IN PARTICIPANTS WITH DIABETIC RETINOPATHY. Sponsor: Perfuse Therapeutics, Inc.
- Lotus (EBS-105-01): A Phase 1b Study of a Novel Multivalent Fusion Antibody (EB-105) in Subjects with Diabetic Macular Edema (DME). Sponsor: Eluminex Biosciences, Inc. (USA)
- Ashvattha (D-4517-002): A Two Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME). Stage 2: Visual Examiner-Masked, Randomized Active, Sham and Placebo Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Subcutaneously Administered D-4517.2 to Subjects with Neovascular (wet) Age-Related Macular Degeneration. Sponsor: Ashvattha Therapeutics, Inc.
- GR43828 (GR43828): A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7446603 ADMINISTERED ALONE OR IN COMBINATION WITH AFLIBERCEPT OR FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA. Sponsor: Genentech, Inc.
- OTX-TKI-2022-101 (OTX-TKI-2022-101): A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (axitinib implant) for Intravitreal Injection in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy. Sponsor: Ocular Therapeutix, Inc.
- Archway (GR40548): A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Sponsor: F. Hoffmann-La Roche Ltd.
- Graybug (GBV-102-002): A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration. Sponsor: Graybug Vision, Inc.
- GTScope (GTScope): A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Gyroscope Therapeutics
- Pavilion (GR41675): A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY. Sponsor: F. Hoffmann-La Roche Ltd.
- Gather2 (ISEE2008): A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURATM (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Sponsor: IVERIC bio, Inc.
- New Day (01-20-005): A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (DME). Sponsor: Alimera Sciences, Inc.
- COOL-3 (COOL-3): A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia as Local Anesthesia for Patients Receiving Intravitreal Injections. Sponsor: RecensMedical, Inc.
- GR42163 (GR42163): A PHASE Ia, MULTICENTER, OPEN-LABEL, SINGLE-DOSE, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVITREAL INJECTIONS OF RO7303359 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Sponsor: Genentech, Inc.
- Horizon (GT005-03): A PHASE II, OPEN-LABEL, OUTCOMES-ASSESSOR MASKED, MULTICENTRE, RANDOMISED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO DOSES OF GT005 ADMINISTERED AS A SINGLE SUBRETINAL INJECTION IN SUBJECTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION. Sponsor: GYROSCOPE THERAPEUTICS
- NGM (NGM621-GA-201): A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). Sponsor: NGM Biopharmaceuticals, Inc.
- IONIS (ISIS 696844-CS5): A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). Sponsor: Ionis Pharmaceuticals, Inc.
- SCD (SCD411-CP101): A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration. Sponsor: SamChunDang Pharm. Co. Ltd.
- DC002842 (DC002842): CHARACTERIZATION OF AQUEOUS HUMOR AND PLASMA FROM PATIENTS WITH AND WITHOUT GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Sponsor: Genentech, Inc.
- Unity 02 (UBX1325-02): A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema. Sponsor: UNITY Biotechnology, Inc.
- Unity 03 (UBX1325-03): A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration. Sponsor: UNITY Biotechnology, Inc.
- Sandoz PFS (CSOK583A12304): An open-label, single-arm, multicenter study in patients with neovascular age-related macular degeneration to evaluate the safety of SOK583A1 (40 mg/mL), a proposed aflibercept biosimilar product, provided in a prefilled syringe. Sponsor: Sandoz Inc.
- Sandoz Vial (CSOK583A12303): An open-label, single-arm, multicenter study in patients with neovascular age-related macular degeneration to evaluate the safety of SOK583A1 (40 mg/mL), a proposed aflibercept biosimilar product, provided in a vial kit. Sponsor: Sandoz Inc.
- Pavia (EYP-1901-204): A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR). Sponsor: EyePoint Pharmaceuticals, Inc.
- Davio (EYP-1901-201): A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD. Sponsor: EyePoint Pharmaceuticals, Inc.
- COOL-3 2.0 (COOL-3s): A Randomized, Double- Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia as Local Anesthesia for Patients Receiving Intravitreal Injections. Sponsor: RecensMedical, Inc.
- Unity 04 (UBX1325-04): A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema. Sponsor: UNITY Biotechnology, Inc.
- PD-CP-Y1 (PD-CP-Y1): A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration. Sponsor: Rophibio Inc.
- RHINE (GR40398): Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) In Patients with Diabetic Macular Edema. Sponsor: F. Hoffmann-La Roche Ltd
- Lucerne (GR40844): Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration Sponsor: F. Hoffmann-La Roche Ltd
- Kingfisher (CRTH258B2305): Phase III, A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment. Sponsor: Novartis
- Outlook (ONS-5010-002): Phase III, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Sponsor: Outlook Therapeutics, Inc
- Gallego (G40973): Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, And Efficacy of Intravitreal Injections of FHTR2163 In Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Sponsor: F. Hoffmann-La Roche Ltd
- SalutarisMD (SMD-5010): Phase I, A prospective study of episcleral brachytherapy for the treatment of neovascular age-related macular degeneration. Sponsor: Salutaris Medical Devices Inc.
- Canberra (BP41321): Phase II, A Randomized, double-masked, 48-Week, Parallel-Group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG774 in patients with diabetes mellitus type 1 or type 2 with treatment-naive diabetic retinopathy. Sponsor: F. Hoffmann-La Roche Ltd
- Candela (VGTe (HD)-AMD-1905): Phase II, A Randomized, single-masked, active-controlled, tolerability and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration. Sponsor: Regeneron Pharmaceuticals, Inc.
- Photon (VGFTe (HD)-DME-1934): Phase II/III, A randomized, double-masked, active –controlled study of efficacy and safety of high-dose aflibercept in patient with diabetic macular edema. Sponsor: Regeneron Pharmaceuticals, Inc.
- Balaton (GR41984): Phase III, multicenter, randomized, double masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal occlusion. Sponsor: F. Hoffmann-La Roche Ltd
- Comino (GR41986): Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal vein occlusion. Sponsor: F. Hoffmann-La Roche Ltd
- Rhone-X (GR41987): Phase III, A MULTICENTER, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OFFARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA. Sponsor: F. Hoffmann-La Roche Ltd
- Gallego-LE (G42558): Phase II, A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Sponsor: Genentech, Inc.
- Sandoz (CSOK583A12301): Phase III, A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration. Sponsor: Hexal AG and Sandoz Inc.
- Norse 3 (ONS-5010-003): Phase III, A 3-MONTH STUDY TO ASSESS THE SAFETY OF ONS-5010 IN SUBJECTS WITH VISUAL IMPAIRMENT DUE TO RETINAL DISORDERS. Sponsor: Outlook Therapeutics, Inc
- Alkahest (AKST4290-231): Phase II, A DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF ORAL AKST4290 IN PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE DIABETIC RETINOPATHY (CAPRI). Sponsor: Alkahest, Inc.
- Altimeter (MR41926): Phase IIb, AN EXPLORATORY, PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM, INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH FARICIMAB (RO6867461). Sponsor: F. Hoffmann-La Roche Ltd
- NAB (RGX-314-0101): Serum Anti-AAV8 Neutralizing Antibody Assessment Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy. Sponsor: REGENXBIO Inc.
- INTEGRAL (THR-687-002): Phase II, Randomized, multicenter study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular oedema (DME). Sponsor: Oxurion NV
- Bluetail (BP40923): A MULTI-CENTER, NON-RANDOMIZED, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200394 FOLLOWING INTRAVITREAL ADMINISTRATION IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Sponsor: F. Hoffmann-La Roche Ltd
- Kalahari (THR-149-002): Phase II, randomized, multicenter study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME). Sponsor: Oxurion NV
- Rezolute (RZ402-201): Phase II, A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants with Diabetic Macular Edema (DME). Sponsor: Rezolute, Inc.
- Dream (OTT166-201): Phase II, Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR). Sponsor: OcuTerra Therapeutics, Inc.
- AVD-104-C301: Phase 2 Study to Evaluate the Safety and Treatment Effect of Intravitreal AVD-104 in Participants with Diabetic Macular Edema. Sponsor: Aviceda Therapeutics, Inc.
- Amend (QA102-CS201): PHASE II, DOUBLE-MASKED, RANDOMIZED, PLACEBO- CONTROLLED, DOSE-RESPONSE STUDY ASSESSING THE SAFETY AND EFFICACY OF QA102 IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENERATION (AMD). Sponsor: Smilebiotek Zhuhai Limited
- Sandcat (GR44278): PHASE III, MULTICENTER, RANDOMIZED, DOUBLE‐MASKED, SHAM‐CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA. Sponsor: F. Hoffmann‐La Roche Ltd
- OLIX (OLX10212-01): Phase I, Multicenter, Open-Label, Single- and Multi-Dose, Dose-Escalating Clinical Study to Evaluate the Safety and Tolerability of OLX10212 Administered by Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: OliX Pharmaceuticals, Inc.
- Quasar (22153): Phase III, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. Sponsor: Bayer AG
- Norse Eight (ONS-5010-008): Phase III, Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects with Neovascular Age-related Macular Degeneration; NORSE EIGHT. Sponsor: Outlook Therapeutics Inc.
- GAZE (4D-175-C001): Phase I, A Clinical Trial to Evaluate Intravitreal 4D-175 Gene Therapy in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration. Sponsor: 4D Molecular Therapeutics, Inc.
- BREYE (BREYE-C22-1005): Phase 1b, open-label, dose-escalating study evaluating the safety,tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema. Sponsor: Breye Therapeutics
